Katherine A. Freitas

Katherine A. Freitas

Auto-generated profile, based on publicly available information

Katherine A. Freitas

Immunology Graduate Program, Stanford University School of Medicine, Stanford, CA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2022 in Science
Verified
Journal Article
Closed access
KFKatherine A. Freitas
Katherine A. Freitas
JBJulia A. Belk
Julia A. Belk
ESElena Sotillo
Elena Sotillo
PQPatrick J. Quinn
Patrick J. Quinn
MRMaria C. Ramello
Maria C. Ramello
CMCrystal L. Mackall
Crystal L. Mackall
T cells are the major arm of the immune system responsible for controlling and regressing cancers. To identify genes limiting T cell function, we conducted genome-wide CRISPR knockout screens in human chimeric antigen receptor (CAR) T cells. Top hits were MED12 and CCNC , components of the Mediator kinase module. Targeted MED12 deletion enhanced antitumor activity and sustained the effector phenotype in CAR- and T cell receptor–engineered T cells, and inhibition of CDK8/19 kinase activity increased expansion of nonengineered T cells. MED12 -deficient T cells manifested increased core Meditator chromatin occupancy at transcriptionally active enhancers—most notably for STAT and AP-1 transcription factors—and increased IL2RA expression and interleukin-2 sensitivity. These results implicate Mediator in T cell effector programming and identify the kinase module as a target for enhancing potency of antitumor T cell responses.